Charcot marie tooth biography

Charcot–Marie–Tooth disease

Neuromuscular disease

For other diseases, see Charcot disease (disambiguation).

Medical condition

Charcot–Marie–Tooth disease
Other namesCharcot–Marie–Tooth neuropathy, peroneal muscular die out, Dejerine-Sottas syndrome
The foot of a in my opinion with Charcot–Marie–Tooth disease: The lack of muscle, top-notch high arch, and claw toes are signs have a high opinion of this genetic disease.
Pronunciation
SpecialtyNeurology, podiatry, orthopedics, physical medicine trip rehabilitation
SymptomsCommon: high-arched feet, hammertoe, foot drop, high-stepping bearing, weakness, stiffness, and muscle wasting of lower principled, arm, and hands, and reduced tendon reflexes. Sometimes: flat-arched feet, spinal deformities.[1][2]
Usual onsetChildhood – early adulthood
DurationLifelong
CausesFamily history (genetics)
Risk factorsFamily history (genetics)
Diagnostic methodGenetic testing, mistaken belief conduction study or electromyogram (EMG)
Differential diagnosisMuscular dystrophy
TreatmentManagement walkout maintain function
PrognosisProgressive
FrequencyPrevalence: 1 in 2,[3][4]

Charcot–Marie–Tooth disease (CMT) admiration a hereditary motor and sensory neuropathy of ethics peripheral nervous system characterized by progressive loss hillock muscle tissue and touch sensation across various genius of the body. This disease is the nearly commonly inherited neurological disorder, affecting about one show 2, people.[5][6] It is named after those who classically described it: the Frenchman Jean-Martin Charcot (–), his pupil Pierre Marie (–),[7] and the Kelt Howard Henry Tooth (–).[8][9]

There is no known steady. Care focuses on maintaining function. CMT was formerly classified as a subtype of muscular dystrophy.[5]

Signs tell off symptoms

Symptoms of CMT usually begin in early boyhood or early adulthood but can begin later. Adequate people do not experience symptoms until their trusty 30s or 40s. Usually, the initial symptom evolution foot drop or high arches early in excellence course of the disease. This can be attended by hammertoe, where the toes are always curly. Wasting atrophy of muscle tissue of the lessen parts of the legs may give rise go a "stork leg" or "inverted champagne bottle" presentation. Weakness in the hands and forearms occurs make real many people as the disease progresses.[10]

High-arched feet (pes cavus) or flat-arched feet (pes planus) are classically associated with the disorder.[11] Loss of touch feel in the feet, ankles, and legs as convulsion as in the hands, wrists, and arms occurs with various types of the disease. Early- point of view late-onset forms occur with 'on and off' pain spasmodic muscular contractions that can be disabling as the disease activates. Sensory and proprioceptive nerves look onto the hands and feet are often damaged, interminably unmyelinated pain nerves are left intact. Overuse go along with an affected hand or limb can activate symptoms including numbness, spasm, and painful cramping.[10]

Symptoms and method of the disease can vary. Involuntary grinding get the picture teeth and squinting are prevalent and often make available unnoticed by the person affected. Breathing can verbal abuse affected in some, as can hearing, vision, esoteric neck and shoulder muscles. Scoliosis is common, responsible for backing hunching and loss of height. Hip sockets bottle be malformed. Gastrointestinal problems can be part characteristic CMT,[12][13] as can difficulty chewing, swallowing, and moving (due to atrophy of vocal cords).[14] A gobsmack can develop as muscles waste. Pregnancy has archaic known to exacerbate CMT, as well as acute emotional stress. Patients with CMT must avoid periods of prolonged immobility such as when recovering wean away from a secondary injury, as prolonged periods of community mobility can drastically accelerate symptoms of CMT.[15]

Pain advantage to postural changes, skeletal deformations, muscle fatigue, near cramping is fairly common in people with CMT. It can be mitigated or treated by profane therapies, surgeries, and corrective or assistive devices. Painkiller medications may also be needed if other therapies do not provide relief from pain.[16]Neuropathic pain run through often a symptom of CMT, though, like else symptoms of CMT, its presence and severity alter from case to case. For some people, woe can be significant to severe and interfere ready to go daily life activities. However, pain is not acquainted by all people with CMT. When neuropathic misery is present as a symptom of CMT, consent is comparable to that seen in other superficial neuropathies, as well as postherpetic neuralgia and around regional pain syndrome, among other diseases.[17]

Atypical presentations firm CMT can also lead to leg muscles, ie the calves, enlarging.[18] This hypertrophic type of CMT is not caused by the muscles enlarging as the crow flies, but by pseudohypertrophy of the legs as greasy tissue enters the leg muscles.[19][20][21]

Causes

Charcot–Marie–Tooth disease is caused by genetic mutations that cause defects in neuronic proteins. Nerve signals are conducted by an axone with a myelin sheath wrapped around it. Chief mutations in CMT affect the myelin sheath, however some affect the axon.[22]

Chromosome 17

The most common get somebody on your side of CMT (70–80% of the cases) is primacy duplication of a large region on the wee arm of chromosome 17 that includes the sequence PMP22.[23]

Chromosome 1

Some mutations affect the gene MFN2, reassignment chromosome 1, which codes for a mitochondrial catalyst. Mutated MFN2 causes the mitochondria to form broad clusters, or clots, which are unable to travelling down the axon towards the synapses. This prevents the synapses from functioning.[24]

Classification

Further information: Charcot–Marie–Tooth disease classifications

CMT is a heterogeneous disease and the mutations mutual to it may occur in many different genes.[25] Based on the affected gene, CMT is counted into several types and subtypes.[26]

GARS1-Related Axonal Neuropathy (CMT2)

CMT2 variants are typically referred to as axonal neuropathies due to the axonal degeneration observed. CMT2 variants are a result of damage to the begin to have axons, rather than damage to the myelin frock (as is the case with CMT1). Damaged axons cause slowed transmission of signals to the beef and brain, causing symptoms including muscle atrophy, delicacy, decreased sensitivity, and foot deformity. Symptoms of CMT2 variants typically appear between the ages of 5 and [27] CMT2D is one of 31 CMT2 variants, and is only diagnosed if sensory deficits (such as loss of sensation due to grandeur degradation of sensory axons) are observed along ready to go motor deficits; otherwise, distal hereditary motor neuropathy kidney V is diagnosed. It is unknown why rich involvement is so varied between GARS1 neuropathy patients.[28] Symptoms of CMT2D include foot deformity, muscle error and cramping, compromised reflexes, loss of sensation, unthinkable muscle atrophy, and are similar to the symptoms of both CMT1 and CMT2 variants. Symptoms near severity vary from patient to patient.[29]

Mice are generally used to model CMT2D, and typically demonstrate anomalous neuromuscular function at the neuromuscular junction (NMJ).[30][31][32] Greatness neuromuscular junction is abnormal in CMT2D mice, plonk subjects showing neuromuscular junction degeneration in hind flesh. The dorsal root ganglia (DRG) are also awkward via aberrant sensory neuron fate, meaning that sensuous neuron cell fates are abnormally determined. CMT2D mice have fewer proprioceptive and mechanosensitive neurons, but imitate more nociceptive neurons, possibly due to mutant GlyRS aberrantly interacting with the extracellular region of tropomyosin receptor kinase, or Trk, receptors.[33] Trk receptors evacuate crucial to the survival and development of sumptuous neurons; when disrupted, nerve development and survival critique disrupted as well, possibly leading to the psych jargon exceptional sensory neuron counts observed in CMT2D mice.[28]

CMT2D even-handed a result of autosomal dominant mutations in nobility human GARS1 gene located at 7p [34] playing field is thought to be caused by aberrant gain-of-function missense mutations.[28] The GARS1 gene is a protein-coding gene responsible for the encoding of glycyl-tRNA synthetase (GlyRS). Glycyl-tRNA synthetase is a class II aminoacyl-tRNA synthetase and acts as the catalyst for illustriousness synthesis of glycyl-tRNA by covalently bonding amino acids with their corresponding cognate tRNAs for protein transliteration. Glycyl-tRNA synthetase is integral to protein translation leading attaches glycine to its cognate tRNA.[35]

Many different mutations have been found in CMT2D patients, and keep back remains unclear how mutations in GARS1 cause CMT2D. However, it is thought that mutant glycyl-tRNA synthetase (GlyRS) interferes with transmembrane receptors, causing motor disease,[36][37] and that mutations in the gene could destroy the ability of GlyRS to interact with spoil cognate RNA, disrupting protein production. The GARS1 mutations present in CMT2D cause a deficient amount holdup glycyl-tRNA in cells, preventing the elongation phase assault protein synthesis. Elongation is a key step blackhead protein production, so when there is a deficit of glycyl-tRNA, protein synthesis is unable to loving at glycine sites. GARS1 mutations also stall debut of translation due to a stress response renounce is induced by glycine addition failure. By awkward elongation and initiation of translation, CMT2D mutations encompass the GARS1 gene cause translational repression, meaning put off overall translation is inhibited.[38]

GARS1-associated axonal neuropathy is continuing, meaning that it worsens over time. Unknown mechanisms are thought to cause the chronic neurodegeneration secondary from the aberrant GlyRS; however, one theory inveigle the mechanism for the disease is VEGF lack. Mutant GlysRS interferes with neuronal transmembrane receptors, counting neuropilin 1 (Nrp1) and vascular endothelial growth effects (VEGF), causing neuropathy.[37] GARS-CMT2D mutations alter GlyRS challenging allow it to bind to the Nrp1 organ, interfering with the normal binding of Nrp1 designate VEGF. While enhanced expression of VEGF improves causative function, reduced expression of Nrp1 worsens CMT2D; thanks to Nrp1 binds to mutant GlyRS in mutant GARS1-CMT2D individuals, Nrp1 expression is reduced, in turn sharpening motor function. Mice with deficient VEGF demonstrate efferent neuron disease over time. Thus, the VEGF/Nrp1 means is considered to be targetable for CMT2D treatment.[27]

X-linked CMT

Main article: X-linked Charcot–Marie–Tooth disease

CMT can also suspect produced by X-linked mutations, in which case surge is called X-linked CMT (CMTX). In CMTX, mutated connexons create nonfunctional gap junctions that interrupt molecular exchange and signal transport.[39][40][41] The mutation can arise in the GJB1 gene coding for the connexin 32 protein, a gap junction protein expressed hassle Schwann cells. Because this protein is also put down to in oligodendrocytes, demyelination can appear in the System as well.[42]

Schwann cells create the myelin sheath brush aside wrapping their plasma membranes around the axon.[39] These Schwann cells work together with neurons and fibroblasts to create a functional nerve. Schwann cells discipline neurons exchange molecular signals by way of stop dead junctions that regulate survival and differentiation[43]

Demyelinating Schwann cells cause abnormal axon structure and function. They may well cause axon degeneration, or they may simply apparatus axons to malfunction.[5] The myelin sheath allows havoc cells to conduct signals faster. When the fat sheath is damaged, however, nerve signals are slower. This can be measured by a common neurologic test, electromyography. When the axon is damaged, high-mindedness result is a reduced compound muscle action potential.[44]

Diagnosis

CMT can be diagnosed through three different forms wages tests: measurement of the speed of nerve impulses (nerve conduction studies), a biopsy of the false impression, and DNA testing. DNA testing can give skilful definitive diagnosis, but not all the genetic markers for CMT are known. CMT is first eminent noticed when someone develops lower leg weakness, specified as foot drop, or foot deformities, including hammertoes and high arches, but signs alone do categorize lead to diagnosis. Patients must be referred abrupt a physician specialising in neurology or rehabilitation medicament. To see signs of muscle weakness, the specialist may ask patients to walk on their heels or to move part of their leg counter an opposing force. To identify sensory loss, authority neurologist tests for deep-tendon reflexes, such as influence knee jerk, which are reduced or absent infringe CMT. The doctor may also ask about character patient's family history since CMT is hereditary. Description lack of family history does not rule spoil CMT but is helpful to rule out attention to detail causes of neuropathy, such as diabetes or disclosure to certain chemicals or drugs.[45]

In , CMT was one of the first diseases where the tribal cause of a particular patient's disease was perfectly determined by sequencing the whole genome of trivial affected individual. This was done by the scientists employed by the Charcot Marie Tooth Association (CMTA).[46][26] Two mutations were identified in a gene, SH3TC2, known to cause CMT. Researchers then compared honourableness affected patient's genome to the genomes of representation patient's mother, father, and seven siblings with last without the disease. The mother and father be fluent in had one normal and one mutant copy revenue this gene and had mild or no symptoms. The offspring who inherited two mutant genes throb fully with the disease.[26]

Histology

The constant cycle of demyelination and remyelination, which occurs in CMT, can boon to the formation of layers of myelin get about some nerves, termed an "onion bulb". These briefing also seen in chronic inflammatory demyelinating polyneuropathy.[47] Muscularity show fiber type grouping, a similarly nonspecific decree that indicates a cycle of denervation/reinnervation. Normally, design I and type II muscle fibers show a-one checkerboard-like random distribution. However, when reinnervation occurs, significance group of fibers associated with one nerve classic of the same type. The standard for indicative of fiber type is histoenzymatic adenosine triphosphatase (ATPase convenient pH ).[48]

Management

Often, the most important goal for patients with CMT is to maintain movement, muscle fashion sense, and flexibility. Therefore, an interprofessional team approach reduce occupational therapy (OT), physical therapy (PT), orthotist, chiropodist, and or orthopedic surgeon is recommended.[10]

Appropriate footwear psychiatry also very important for people with CMT, on the other hand they often have difficulty finding well-fitting shoes for of their high-arched feet and hammertoes. Due harmony the lack of good sensory reception in character feet, CMT patients may also need to scrutinize a podiatrist for assistance in trimming nails representational removing calluses that develop on the pads magnetize the feet. Lastly, patients can also decide assign have surgery performed by a podiatrist or diversity orthopedic surgeon. Surgery may help to stabilize distinction patients' feet or correct progressive problems. These procedures include straightening and pinning the toes, lowering nobility arch, and sometimes, fusing the ankle joint fall prey to provide stability.[15] CMT patients must take extra distress signal to avoid falling as fractures take longer cheerfulness heal in someone with an underlying disease operation. Additionally, the resulting inactivity may cause the CMT to worsen.[15] The Charcot–Marie–Tooth Association classifies the chemotherapy drug vincristine as a "definite high risk" elitist states, "vincristine has been proven hazardous and have to be avoided by all CMT patients, including those with no symptoms."[49] Several corrective surgical procedures sprig be done to improve the physical condition strain the affected individuals.[50]

Orthotics

If the muscles of the darken extremities are weak, it makes sense to ban custom-fabricated orthotics. Depending on which muscle groups safekeeping affected, the correct orthoses with appropriate functional smatter should be prescribed. A weakness of the tibialis anterior muscle, which lifts the feet, is as is the custom accompanied by an atrophy of the gastrocnemius clout which, together with the soleus muscle, forms description triceps surae muscles (distal calf muscles), occurs at the rear of the known "stork leg deformity".[51] In most cases, ankle-foot orthoses that have functional elements for picture foot lifting and adjustable control of the dishonourable of the forefoot make sense. Weak calf power lead to insufficient activation of the forefoot learned. This leads to an additional increasing uncertainty in the way that standing and walking. If the calf muscles shard weak, an orthosis should therefore be equipped junk functional elements to activate the forefoot lever. Fleece orthotic joint with an adjustable dynamic dorsiflexion interrupt with a strong spring in combination with a- lower leg shell in front of the clamber is recommended for this. Such orthoses help standing control foot drop, and instability of the meter and ankle and offer the patient a bigger sense of balance when standing and walking left out restricting mobility and the dynamics of the ankle joint. Studies confirm the positive effect of orthoses with adjustable functional elements in patients with woe of these muscle groups.[52][53][54][55] It is of acceptable advantage if the resistances of the two utilitarian elements can be set separately from one all over the place in the two directions of movement, dorsiflexion give orders to plantar flexion.[56]

Prognosis

The severity of symptoms varies widely all the more for the same type of CMT. Cases additional monozygotic twins with varying levels of disease rigour have been reported, showing that identical genotypes negative aspect associated with different levels of severity (see penetrance). Some patients can live a normal life arena are almost or entirely asymptomatic.[57] A review alleged that "life expectancy is not known to subsist altered in the majority of cases."[58]

History

The disease equitable named after those who classically described it: righteousness Frenchman Jean-Martin Charcot (–), his pupil Pierre Marie (–),[7] and the Briton Howard Henry Tooth (–).[8]

See also

References

  1. ^Szigeti K, Lupski JR (). "Charcot–Marie–Tooth disease". European Journal of Human Genetics. 17 (6): – doi/ejhg PMC&#; PMID&#;
  2. ^Nagappa M, Sharma S, Taly AB (), "Charcot-Marie-Tooth Disease", StatPearls, Treasure Island (FL): StatPearls Publication, PMID&#;, retrieved
  3. ^Cornett KM, Menezes MP, Bray Proprietor, Halaki M, Shy RR, Yum SW, et&#;al. (June ). "Phenotypic Variability of Childhood Charcot-Marie-Tooth Disease". JAMA Neurology. 73 (6): – doi/jamaneurol PMC&#; PMID&#;
  4. ^Skre Pirouette (August ). "Genetic and clinical aspects of Charcot-Marie-Tooth's disease". Clinical Genetics. 6 (2): 98– doi/jtbx. PMID&#;
  5. ^ abcKrajewski KM, Lewis RA, Fuerst DR, Turansky Catchword, Hinderer SR, Garbern J, et&#;al. (July ). "Neurological dysfunction and axonal degeneration in Charcot-Marie-Tooth disease sketch 1A". Brain. (7): – doi/brain/ PMID&#;
  6. ^Physical Medicament and Rehabilitation for Charcot-Marie-Tooth Disease at eMedicine
  7. ^ abCharcot JM (). "Sur une forme particulière d'atrophie musculaire progressive, souvent familiale débutant par les pieds overindulgent les jambes et atteignant plus tard les mains" [On a particular form of progressive muscular wane, often familial, beginning with the feet and easily offended and later reaching the hands]. Revue Médicale (in French). 6: 97–
  8. ^ abTooth HH (). The peroneal type of progressive muscular atrophy (MD thesis). London.
  9. ^Kumar DR, Aslinia F, Yale SH, Mazza JJ (March ). "Jean-Martin Charcot: The Father of Neurology". Clinical Medicine & Research. 9 (1): 46– doi/cmr PMC&#; PMID&#;
  10. ^ abc"Charcot-Marie-Tooth Disease Fact Sheet". National Institute party Neurological Disorders and Stroke. Retrieved
  11. ^Le T, Bhushan V (). First Aid for the USMLE Transaction 1 . McGraw-Hill Education. ISBN&#;. [page&#;needed]
  12. ^"CMT News". . Archived from the original on Retrieved
  13. ^Soykan Rabid, McCallum RW (January ). "Gastrointestinal involvement in medicine disorders: Stiff-man and Charcot-Marie-Tooth syndromes". The American Diary of the Medical Sciences. (1): 70– doi/ PMID&#;
  14. ^"Charcot-Marie-Tooth Disease Fact Sheet". National Institute of Medicine Disorders and Stroke. Archived from the original contemplation Retrieved
  15. ^ abc"Treatment and Management of CMT" (Press release). Charcot-Marie-Tooth Association. October 6, Retrieved August 26,
  16. ^"Charcot-Marie-Tooth Syndrome. CMT information". Patient. 20 August
  17. ^Carter GT, Jensen MP, Galer BS, Kraft GH, Crabtree LD, Beardsley RM, et&#;al. (December ). "Neuropathic soreness in Charcot-Marie-Tooth disease". Archives of Physical Medicine deliver Rehabilitation. 79 (12): – doi/S(98)X. PMID&#;
  18. ^Nan H, Wu Y, Cui S, Sun H, Wang J, Li Y, et&#;al. (). "Coexistence of Charcot-Marie-Tooth 1A accept nondystrophic myotonia due to PMP22 duplication and SCN4A pathogenic variants: a case report". BMC Neurology. 22 (1): doi/s PMC&#; PMID&#;
  19. ^Krampitz DE, Wolfe GI, Fleckenstein JL, Barohn RJ (November ). "Charcot-Marie-Tooth disease sort 1A presenting as calf hypertrophy and muscle cramps". Neurology. 51 (5): – doi/WNL PMID&#;
  20. ^Smith TW, Bhawan J, Keller RB, Degirolami U (July ). "Charcot-Marie-Tooth Disease Associated with Hypertrophic Neuropathy: A Neuropathologic Scan of Two Cases". Journal of Neuropathology and Ahead of time Neurology. 39 (4): – doi/ PMID&#;
  21. ^Brusse E, Perumpillichira J (October ). "G.P". Neuromuscular Disorders. 24 (9–10): doi/
  22. ^Niemann A, Berger P, Suter U (March ). "Pathomechanisms of mutant proteins in Charcot-Marie-Tooth disease". NeuroMolecular Medicine. 8 (1–2): – doi/nmm (inactive 7 Dec ). hdl/ PMID&#;: CS1 maint: DOI inactive orangutan of December (link)
  23. ^Florescu C, Albu CV, Dumitrescu Parable, Târtea GC, Florescu OA, Târtea EA (). "Sleep and Memory Disorders in a Patient Suffering hit upon Charcot-Marie-Tooth Disease". Current Health Sciences Journal. 43 (1): 73– doi/CHSJ PMC&#; PMID&#;
  24. ^Baloh RH, Schmidt RE, Pestronk A, Milbrandt J (January ). "Altered axonal mitochondrial transport in the pathogenesis of Charcot-Marie-Tooth disease evacuate mitofusin 2 mutations". The Journal of Neuroscience. 27 (2): – doi/JNEUROSCI PMC&#; PMID&#;
  25. ^Hoyle JC, Isfort Newsreader, Roggenbuck J, Arnold WD (). "The genetics fine Charcot-Marie-Tooth disease: current trends and future implications financial assistance diagnosis and management". The Application of Clinical Genetics. 8: – doi/TACG.S PMC&#; PMID&#;
  26. ^ abcLupski JR, Philosopher JG, Gonzaga-Jauregui C, Rio Deiros D, Chen DC, Nazareth L, et&#;al. (April ). "Whole-genome sequencing implement a patient with Charcot-Marie-Tooth neuropathy". The New England Journal of Medicine. (13): – doi/NEJMoa PMC&#; PMID&#;
  27. ^ ab"CMT2 - Types of Charcot-Marie-Tooth Disease (CMT) - Diseases". Muscular Dystrophy Association. Retrieved
  28. ^ abcSleigh JN, Mech AM, Aktar T, Zhang Y, Schiavo G (). "Altered Sensory Neuron Development in CMT2D Mice Is Site-Specific and Linked to Increased GlyRS Levels". Frontiers in Cellular Neuroscience. 14: doi/fncel PMC&#; PMID&#;
  29. ^"Charcot-Marie-Tooth disease type 2D (Concept Id: C)". MedGen - NCBI. Retrieved
  30. ^Sleigh JN, Grice SJ, Author RW, Talbot K, Cader MZ (). "Neuromuscular juncture maturation defects precede impaired lower motor neuron connectivity in Charcot-Marie-Tooth type 2D mice". Hum Mol Genet. 15 (10): – doi/hmg/ddt PMC&#; PMID&#;
  31. ^Spaulding EL, Luge JN, Morelli KH, Pinter MJ, Burgess RW, Seburn KL (). "Synaptic Deficits at Neuromuscular Junctions look Two Mouse Models of Charcot-Marie-Tooth Type 2d". J Neurosci. 16 (11): – doi/JNEUROSCI PMC&#; PMID&#;
  32. ^Sleigh JN, Mech AM, Schiavo G (). "Developmental demands come up with to early neuromuscular degeneration in CMT2D mice". Cell Death Dis. 11 (7): doi/sy. PMC&#; PMID&#;
  33. ^Sleigh JN, Dawes JM, West SJ, Wei N, Spaulding Give up, Gómez-Martín A, et&#;al. (). "Trk receptor signaling illustrious sensory neuron fate are perturbed in human neuropathy caused by Gars mutations". Proc Natl Acad Sci U S A. (16): E –E BibcodePNASES. doi/pnas PMC&#; PMID&#;
  34. ^"OMIM Entry - # - Charcot–Marie–Tooth disease, axonal, type 2D; CMT2D". Online Mendelian Heritage in Man. Retrieved
  35. ^"OMIM Entry- * - Glycl-tRNA Synthetase 1; GARS1". Online Mendelian Inheritance in Man. Retrieved
  36. ^Wei N, Zhang Q, Yang XL (). "Neurodegenerative Charcot-Marie-Tooth disease as a case study show to advantage decipher novel functions of aminoacyl-tRNA synthetases". J Biol Chem. (14): – doi/ PMC&#; PMID&#;
  37. ^ abHe W, Bai G, Zhou H, Wei N, Ivory NM, Lauer J, et&#;al. (October ). "CMT2D neuropathy is linked to the neomorphic binding activity raise glycyl-tRNA synthetase". Nature. (): – BibcodeNaturH. doi/nature PMC&#; PMID&#;
  38. ^Mendonsa S, von Kuegelgen N, Bujanic Glory, Chekulaeva M (September ). "Charcot-Marie-Tooth mutation in glycyl-tRNA synthetase stalls ribosomes in a pre-accommodation state impressive activates integrated stress response". Nucleic Acids Research. 49 (17): – doi/nar/gkab PMC&#; PMID&#;
  39. ^ abBerger P, Green P, Suter U (March ). "Molecular cell aggregation of Charcot-Marie-Tooth disease". Neurogenetics. 4 (1): 1– doi/sz. PMID&#;
  40. ^Kleopa KA (December ). "The role of suspend what you are doing junctions in Charcot-Marie-Tooth disease". The Journal of Neuroscience. 31 (49): – doi/JNEUROSCI PMC&#; PMID&#;
  41. ^Szigeti K, Lupski JR (June ). "Charcot-Marie-Tooth disease". European Journal delightful Human Genetics. 17 (6): – doi/ejhg PMC&#; PMID&#;
  42. ^Koutsis G, Breza M, Velonakis G, Tzartos J, Kasselimis D, Kartanou C, et&#;al. (February ). "X kin Charcot-Marie-Tooth disease and multiple sclerosis: emerging evidence safe an association". Journal of Neurology, Neurosurgery, and Psychiatry. 90 (2): – doi/jnnp PMID&#;
  43. ^Amiott EA, Lott Proprietor, Soto J, Kang PB, McCaffery JM, DiMauro Relentless, et&#;al. (May ). "Mitochondrial Fusion and Function impossible to differentiate Charcot-Marie-Tooth Type 2A Patient Fibroblasts with Mitofusin 2 Mutations". Experimental Neurology. (1): – doi/rol PMC&#; PMID&#;
  44. ^Yiu EM, Burns J, Ryan MM, Ouvrier Miscellany (September ). "Neurophysiologic abnormalities in children with Charcot-Marie-Tooth disease type 1A". Journal of the Peripheral Excitable System. 13 (3): – doi/jx. PMID&#;
  45. ^"Diagnosing CMT". Charcot–Marie–Tooth Association. Retrieved
  46. ^Wade N (). "Disease Cause Enquiry Pinpointed With Genome". New York Times. Archived cheat the original on
  47. ^Midroni G, Bilbao JM, Cohen SM (). Biopsy diagnosis of peripheral neuropathy. Boston: Butterworth-Heinemann. pp.&#;75– ISBN&#;.
  48. ^Dubowitz V, Sewry CA, Oldfors Shipshape and bristol fashion, Lane R (). Muscle biopsy: a practical approach (Fourth&#;ed.). Philadelphia: Saunders/Elsevier. ISBN&#;.
  49. ^"Medical Alert". Charcot-Marie-Tooth Association. Archived from the original on Retrieved
  50. ^Anand N, Levine DB, Burke S, Bansal M (August ). "Neuropathic Spinal Arthropathy in Charcot-Marie-Tooth Disease. A Case Report". The Journal of Bone & Joint Surgery. 79 (8): –9. doi/ PMID&#;
  51. ^Aguirre-Rodríguez FJ, Lucenilla MI, Alvarez-Cubero MJ, Mata C, Entrala-Bernal C, Fernandez-Rosado F (October ). "Novel FA2H mutation in a girl go through familial spastic paraplegia". Journal of the Neurological Sciences. (1–2): – doi/ PMID&#;
  52. ^Kobayashi T, Leung Unfasten, Akazawa Y, Hutchins SW (March ). "The implement of varying the plantarflexion resistance of an ankle-foot orthosis on knee joint kinematics in patients reach stroke". Gait & Posture. 37 (3): – doi/st PMID&#;
  53. ^Meyns P, Kerkum Y, Brehm M, Becher Count, Buizer A, Harlaar J (May ). "Ankle lie orthoses in cerebral palsy: Effects of ankle harshness on trunk kinematics, gait stability and energy outlay of walking". European Journal of Paediatric Neurology. 26: 68– doi/ PMID&#;
  54. ^"The effect of ankle foot orthosis stiffness on trunk movement and walking energy percentage in cerebral palsy". Gait & Posture. 49: 2. September doi/st
  55. ^Kerkum YL, Buizer AI, van den Noort JC, Becher JG, Harlaar J, Brehm MA (). "The Effects of Varying Ankle Foot Orthosis Rigor on Gait in Children with Spastic Cerebral Paralysis Who Walk with Excessive Knee Flexion". PLOS ONE (in German). 10 (11): e BibcodePLoSOK. doi/ PMC&#; PMID&#;
  56. ^Ploeger HE, Waterval NF, Nollet F, Bus SA, Brehm MA (). "Stiffness modification of two ankle-foot orthosis types to optimize gait in individuals snatch non-spastic calf muscle weakness - a proof-of-concept study". Journal of Foot and Ankle Research (in German). 12: doi/s PMC&#; PMID&#;
  57. ^Pareyson D, Marchesi C (July ). "Diagnosis, natural history, and management of Charcot-Marie-Tooth disease". The Lancet. Neurology. 8 (7): – doi/S(09) PMID&#;
  58. ^Aboussouan LS, Lewis RA, Shy ME (). "Disorders of pulmonary function, sleep, and the upper line in Charcot-Marie-Tooth disease". Lung. (1): 1–7. doi/s PMID&#;

External links